Peregrine Enters Contract Negotiations With U.S. DTRA for Hemorrhagic Fevers
Peregrine Pharmaceuticals, Inc. announced that the company's proposal to investigate its antiviral agent bavituximab and other anti-phosphotidylserine (anti-PS) antibodies as potential therapies for hemorrhagic fever virus (HFV) infections has been selected for a contract award by the Defen ... more
